Drug binding domains of MRP1 (ABCC1) as revealed by photoaffinity labeling

J M Karwatsky1, E Georges

  • 1Institute of Parasitology, McGill University, Quebec, Canada.

Current Medicinal Chemistry. Anti-Cancer Agents
|February 3, 2004
PubMed

Insights

Photoaffinity labeling (PAL) reveals drug binding sites on multidrug resistance protein 1 (MRP1), crucial for understanding and potentially overcoming cancer drug resistance.

Area of Science:

  • Biochemistry and Molecular Biology
  • Cancer Research
  • Pharmacology

Background:

  • Drug resistance is a significant challenge in cancer therapy, limiting treatment efficacy.
  • Multidrug resistance protein 1 (MRP1 or ABCC1) confers resistance by effluxing anticancer drugs from tumor cells.
  • Understanding MRP1's drug binding characteristics is essential for developing strategies to overcome resistance.

Purpose of the Study:

  • To review the application of photoaffinity labeling (PAL) in identifying MRP1 drug binding sites.
  • To summarize knowledge on how various drugs and metabolites interact with MRP1.
  • To highlight the importance of PAL in mapping MRP1's drug-binding domains.

Main Methods:

  • Photoaffinity labeling (PAL) using various photoreactive probes specific to MRP1.
  • Utilizing known MRP1 substrates and drug analogs, including glutathione conjugates.
  • Mapping the binding locations of these probes within MRP1 domains (e.g., transmembrane regions, cytoplasmic loops).

Main Results:

  • PAL studies have identified specific drug binding sites within transmembrane regions (TM 10-11 and 16-17) and cytoplasmic regions (L0, L1) of MRP1.
  • Endogenous substrate LTC(4) and various unconjugated drugs bind to distinct sites within MRP1.
  • Glutathione (GSH)-dependent labeling reveals interactions within TM 16-17 and other regions.

Conclusions:

  • PAL is a powerful technique for characterizing protein-ligand interactions, particularly for membrane transporters like MRP1.
  • Detailed mapping of MRP1 drug binding domains provides critical insights into resistance mechanisms.
  • This knowledge is foundational for designing novel therapeutics to circumvent MRP1-mediated drug resistance.